Allergy Therapeutics (AGY) has reported full-year results to end-June 2024, in line with its July 2024 trading update. Revenues declined by 7% YoY to £55.2m from £59.6m, due to manufacturing capacity constraints, but H2 2024 saw period-over-period growth of 2% (£21.6m vs H2 2023: £21.2m) While this may be regarded as marginal, we believe it represents an important indicator of a stemming in the decline in revenue; and it is the first period of half-year growth since 2021. The implementation of c ....
